Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences Q4 2026 Earnings Report

HeartSciences logo
$2.14 -0.04 (-1.83%)
Closing price 04:00 PM Eastern
Extended Trading
$2.40 +0.26 (+12.10%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
-$0.88
Consensus EPS
-$0.66
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q4 2026
Date
7/23/2026
Time
Before Market Opens
Conference Call Date
Thursday, July 23, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

HeartSciences' Q1 2027 earnings is estimated for Thursday, September 10, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

HeartSciences' Q4 2026 Press ReleasePress Release
(8-K)
HeartSciences' Q4 2026 Annual reportAnnual report
(10-K)

HeartSciences Earnings Headlines

Q1 Earnings Estimate for HeartSciences Issued By Maxim Group
August 2 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30935288
HeartSciences Announces Preliminary Proxy Filing and Fiscal 2026 Results, Highlights Proposed Fortitude Mining Holdings Combination and MyoVista Commercial Progress
July 29, 2026  |  quiverquant.comQ
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
August 3 at 1:00 AM  |  InvestorPlace (Ad)
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335249/0/en/heartsciences-files-preliminary-proxy-statement-for-business-combination-with-fortitude-mining-holdings-provides-business-update-and-reports-fiscal-2026-financial-results.html
HeartSciences Amends Merger Agreement With Fortitude Mining
July 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-amends-merger-agreement-with-fortitude-mining?utm_source=marketbeat.com&utm_medium=referral
111 (NASDAQ:YI) versus HeartSciences (NASDAQ:HSCS) Head to Head Survey
July 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30923629
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools